-
Ugeskrift for laeger · Jun 2006
[Constraints on publication rights in industry-initiated clinical trials--secondary publication].
- Peter C Gøtzsche, Asbjørn Hróbjartsson, Helle Krogh Johansen, Mette T Haahr, Douglas G Altman, and An-Wen Chan.
- H:S Rigshospitalet, Det Nordiske Cochrane Center, DK-2100 København Ø. pcg@cochrane.dk
- Ugeskr. Laeg. 2006 Jun 19; 168 (25): 2467-9.
AbstractIn 22 of 44 industry-initiated clinical trial protocols from 1994-95, it was noted that the sponsor either owned the data or needed to approve the manuscript; another 18 protocols had other constraints. Furthermore, in 16 trials, the sponsor had access to accumulating data, and in an additional 16 trials the sponsor could stop the trial at any time, for any reason. These facts were not noted in any of the trial reports. We found similar constraints on publication rights in 44 protocols from 2004. This tight sponsor control over industry-initiated trials should be changed.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.